I'm raising money for a cause I care about, but I need your help to reach my goal! Please become a supporter to follow my progress and share with your friends.
Subscribe to follow campaign updates!
Padeliporfin vascular targeted photodynamic therapy (VTP) is a cutting-edge treatment for low-grade upper tract urothelial cancer (UTUC), offering a promising alternative to traditional surgical methods. Developed by ImPact Biotech, this innovative therapy combines a photosensitizing drug with laser light to target and eliminate cancer cells. In this article, we delve into the safety profile of Padeliporfin, exploring its efficacy, potential side effects, and the latest updates from the ongoing ENLIGHTED Phase 3 trial.
For more information on Padeliporfin VTP and the latest updates from ImPact Biotech, visit https://impactbiotech.com/.
Padeliporfin VTP is a novel oncology technology platform designed to treat a range of solid tumors, including low-grade UTUC. The therapy involves the intravenous administration of a photosensitizing drug, padeliporfin, followed by the application of near-infrared laser light to the target lesion(s) in the upper tract urothelium. This process triggers a cascade of events leading to vascular occlusion, necrosis, and an anti-tumor immune response.
Efficacy and Safety Profile
Preliminary results from the ENLIGHTED Phase 3 trial have shown encouraging efficacy and safety data. As of the data cut-off date, 12 patients had begun treatment, with nine completing the Induction Treatment Phase (ITP). Key findings include:
Complete Response Rate: 67% (6/9) of patients achieved a complete response at the end of ITP.
Safety and Tolerability: Padeliporfin VTP was well-tolerated, with adverse events mostly Grade 1 or 2. Grade 3 events were observed in three patients, but all resolved within two days. No Grade 4 or 5 serious adverse events were reported.
Ongoing ENLIGHTED Phase 3 Trial
The ENLIGHTED trial is a single-arm, non-randomized, open-label study aiming to enroll 100 patients with low-grade UTUC across 29 global sites. The trial consists of two parts: an Induction Treatment Phase and a Maintenance Treatment Phase. Patients receive one to three courses of VTP therapy at four-week intervals or until a complete response is achieved, followed by standard-of-care treatment alongside VTP therapy administered every three months for up to 12 months.
Recent Updates and Future Directions
50% Enrollment Milestone: The trial has reached 50% patient enrollment, with complete enrollment anticipated for Q1 of 2025.
Additional Data: Interim results presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting showed that 10 out of 13 patients (77%) achieved a complete response, and 3 patients (23%) achieved a partial response.
Orphan Drug Designation: Padeliporfin VTP has received orphan drug designation for use in patients with locally advanced pancreatic cancer, further validating its potential benefits.
Conclusion
Padeliporfin VTP demonstrates early evidence of safety and efficacy in treating low-grade UTUC, offering a promising kidney-sparing alternative to traditional surgical methods. The ongoing ENLIGHTED Phase 3 trial continues to provide encouraging results, with long-term data expected to provide the basis for treatment approval.
Latest 2024 News
ENLIGHTED Trial Progress: The ENLIGHTED trial has reached 50% patient enrollment, with additional data expected to be reported in Q4 of 2024 and complete enrollment anticipated for Q1 of 2025.
ASCO 2024 Presentation: Preliminary results from the ENLIGHTED trial were presented at the 2024 ASCO Annual Meeting, highlighting the efficacy and safety of Padeliporfin VTP in treating low-grade UTUC.
Sign in with your Facebook account or email.